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Abstract
Background: Nicotine replacement therapy (NRT) was licensed for harm reduction in the United 
Kingdom in 2005, and guidance to UK Stop-Smoking Services (SSS) to include long-term partial 
or complete substitution of cigarettes with NRT was issued in 2013. Yet, NRT prevalence data 
and data on changes in biomarkers associated with long-term NRT use among SSS clients are 
scarce.
Methods: SSS clients abstinent 4 weeks postquit date were followed up at 12 months. At baseline 
standard sociodemographic, smoking and SSS use characteristics were collected and of those eli-
gible, 60.6% (1047/1728) provided data on smoking status and NRT use at follow-up. A subsample 
also provided saliva samples at baseline and of those eligible, 36.2% (258/712) provided follow-up 
samples. Saliva was analyzed for cotinine (a metabolite of nicotine) and alpha-amylase (a stress 
biomarker).
Results: Among those who had used NRT during their initial quit attempt (61.5%, 95% CI 58.4%–
64.6%), 6.0% (95% CI 4.3%–8.3%) were still using NRT at 1 year, significantly more ex-smokers than 
relapsed smokers (9.5% vs. 3.7%; p = .005). In adjusted analysis, NRT use interacted with smoking 
status to determine change in cotinine, but not alpha-amylase, levels (Wald χ2 (1) = 13.0, p < .001): 
cotinine levels remained unchanged in relapsed smokers and ex-smokers with long-term NRT use 
but decreased in ex-smokers without long-term NRT use.
Conclusions: Long-term NRT use is uncommon in SSS clients, particularly among relapsed smok-
ers. Its use is associated with continued high intake of nicotine among ex-smokers but does not 
increase nicotine intake in smokers. It does not appear to affect stress response.
Implications: Little is known about the long-term effects of NRT. Given an increasing shift towards 
harm reduction in tobacco control, reducing the harm from combustible products by partial or 
complete substitution with noncombustible products, more data on long-term use are needed. 
This study shows that in the context of SSS, clients rarely use products for up to a year and that 
NRT use does not affect users’ stress response. Ex-smokers using NRT long-term can completely 
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replace nicotine from cigarettes with nicotine from NRT; long-term NRT use by continuing smokers 
does not increase nicotine intake. Long-term NRT appears to be a safe and effective way to reduce 
exposure to combustible nicotine.
Introduction
The main aim of the UK Stop-Smoking Services (SSS) is to support 
attempts to quit smoking. However, not all smokers either feel able 
to or want to stop smoking completely. For this reason, alternative 
approaches have been explored to reduce harm from smoking in this 
population. Harm reduction refers to the reduced psychological or 
physiological harm from substance use without complete cessation.1 
For current smokers, harm reduction may refer to the partial substi-
tution of cigarettes with noncombustible forms of nicotine delivery 
such as nicotine replacement therapy (NRT) to reduce cigarette con-
sumption or for temporary abstinence. For ex-smokers, harm reduc-
tion constitutes the complete, long-term substitution of combustible 
tobacco products (eg, cigarettes) with less harmful noncombustible 
nicotine delivery devices.2 There is good evidence from both popula-
tion studies and clinical trials that the provision of NRT to smokers 
who cut down their cigarette consumption results in more sustained 
decreases in cigarette consumption and improves their chances to 
stop smoking completely.3,4 It increases motivation to stop and 
improves quit rates1,3 but does not increase overall nicotine intake.5,6 
Trials have also shown that extended use of NRT by ex-smokers 
may result in better long-term abstinence rates by reducing relapse.7,8 
For these reasons, NRT has been licensed for harm reduction in the 
United Kingdom since 2005.9,10 Based on a previous report,11 guid-
ance was also issued in 2013 requiring SSS to include partial or com-
plete long-term substitution of cigarettes with NRT in tailored quit 
plans for smokers who have difficulty stopping smoking completely 
so as to help them reduce consumption with the eventual aim to stop 
smoking.12
The vast majority of the harm from smoking is caused by the 
burning of tobacco and not nicotine.13 Thus NRT as a substitute for 
cigarettes is important to study. Although the importance of e-ciga-
rettes for harm reduction purposes cannot be doubted, NRT is likely 
to remain a major component of harm-reduction strategies, given its 
long history in tobacco control and continuing NRT product inno-
vation14 and on-going resistance of some smokers to e-cigarettes.15 
Despite being an established treatment, there is considerable worry 
among potential users16 and stop-smoking advisors17 regarding the 
safety of long-term NRT use, possibly due to misunderstandings 
about the role of nicotine separate from smoked tobacco.18 While 
studies which have looked at this issue find that long-term NRT use 
is safe and any associated health risks small,19 certainly compared 
with continued smoking,20,21 most data come from clinical trials, 
which have samples that tend to differ in important ways from gen-
eral population samples, biasing outcomes.22 Given recent calls for 
further research in the area of harm reduction,12 more studies on 
real-world use are required.
A recent population-based study suggested that only a small per-
centage of ex-smokers continue to use NRT beyond the standard 
length of 3 months and that long-term use is associated with lower 
nicotine intake compared with smokers.6 However, in many indus-
trialized countries most NRT is purchased over the counter,23 rather 
than coupled with specialist behavioral support, which is more effec-
tive.24 Therefore, existing findings may not generalize to smokers 
attending SSS, especially since in this context the NRT provided is 
either free or heavily subsidized. In light of the recent broadening in 
the provision of NRT in SSS, there remains a need to evaluate harm 
reduction with NRT in this context.
This study describes the impact of longer-term NRT use among 
smokers who made a quit attempt with SSS support and agreed to take 
part in the “Evaluating Long Term Outcomes of NHS Stop-Smoking 
Services” (ELONS) study conducted 2012–2014.25 Participants were 
followed up for 1 year and provided information on their NRT use. 
A subset also provided saliva samples which were analyzed for two 
biomarkers of interest: cotinine, the primary metabolite of nicotine 
as a biomarker of exposure; and alpha-amylase, a digestive enzyme 
and indicator of autonomic nervous system activation which corre-
lates with acute and chronic stress, as a biomarker of risk/potential 
harm.26 We included this biomarker as animal research has shown 
that chronic nicotine self-administration can increase stress response 
in rodents.27,28 Specifically, this study aimed to answer the following 
research questions:
1. What is the prevalence of long-term NRT use among smokers 
and ex-smokers who had attempted to stop smoking using SSS?
2. What is the impact of long-term NRT use on biomarkers of nico-
tine exposure and stress among smokers and ex-smokers who 
had attempted to stop smoking using SSS?
Methods
Study Design and Participants
Given the aims of this study, we report only on those with baseline 
and follow-up data. Full details of the study design and sampling 
are provided elsewhere.25 Briefly, as part of the ELONS study, clients 
participating in English SSS who set a quit date were asked if they 
were interested in taking part in a long-term (12 months) evaluation 
of the services by advisors and informed consent was obtained from 
all participants, resulting in a baseline sample of 3045 clients. As 
per standard NHS SSS guidelines, smoking status was recorded at 
4-week follow-up29 and only those who were abstinent at 4 weeks 
(56.7%; 1728/3045) were eligible for long-term follow-up. Of all 
eligible participants for 12  month follow-up, 60.6% (1047/1728) 
could be contacted by telephone to assess smoking status and NRT 
use, thus providing complete baseline and follow-up questionnaire 
data (see Table  1 for participant details). Of those contactable, 
53.3% (558/1047) self-reported as abstinent and were eligible for 
a home visit to verify their smoking status, of whom 4.6% (26/558) 
failed carbon monoxide verification and were therefore reclassified 
as smokers for the purposes of this analysis. The 12-month follow-
up started in April 2013 and finished in March 2014.
A subsample of participants also provided a saliva sample at 
baseline, before their target quit date (61.6%; 1875/3045). Of those 
who were eligible to provide a saliva sample at follow-up (ie, suc-
cessful quitters at 4 weeks with a baseline saliva sample who self-
reported abstinence at 12-month follow-up and therefore had a 
home visit), 52.8% (169/320) provided a sample. Because relapsers 
did not have a home visit (and therefore were not asked to provide 
a saliva sample), an additional random selection of participants with 
baseline saliva samples who had relapsed at 4-week follow-up were 
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contacted at 12 months (83.4%, 392/470) to obtain follow-up saliva 
samples from smokers. Participants were sent a saliva kit through 
the post and asked to return samples directly to UCL. The saliva 
kit contained two Sarstedt Salivettes, a letter from the Principal 
Investigator asking for their help, detailed instructions on sample 
collection and a £10 shopping voucher. Of those approached, 22.6% 
(89/392) returned a saliva sample, resulting in an overall response 
rate from face-to-face or postal collection of 36.2% (258/712) with 
complete baseline and follow-up biomarker data (see Table  1 for 
participant details).
Measures
Questionnaire Items
In addition to standard questions on smoking and sociodemographic 
characteristics, a number of items were included in the baseline 
questionnaire to help evaluate SSS.25 Advisors recorded the types of 
pharmacotherapy and behavioral intervention used during the quit 
attempt. It should be noted that at the time of the study, e-cigarettes 
(another harm reduction tool) were only just becoming popular and 
client use was not routinely recorded by SSS. At 12-month follow-
up, questions related to long-term NRT use were also assessed ret-
rospectively: participants were asked to indicate whether they had 
used NRT for their initial quit attempt and, if so, how long they had 
used NRT for, and if they were still using NRT now. As the use of 
other nicotine-containing products (including e-cigarettes) was not 
assessed at baseline, this was assessed at follow-up only. In order 
to ascertain smoking status and use of NRT in those participants 
who provided a saliva sample through the post and did not receive 
a home visit, these respondents were asked to indicate on a tick box 
included on the salivettes whether they were currently smoking (yes/
no) and used NRT or e-cigarettes (yes/no).
Biomarkers
Saliva samples were collected with Sarstedt Salivettes and stored in 
−20°C freezers, ready for analysis. Saliva was analyzed for cotinine 
by ABS laboratory using rapid liquid–gas chromatograpy30 and for 
alpha-amylase activity by Salimetrics laboratory using an established 
enzyme-kinetic methodology.31 Although alpha-amylase activity is 
largely independent of flow-rate,32 all participants were instructed 
to keep the salivettes in the mouth for the same amount of time 
(1–2 minutes) without chewing as per recommendation.33 In addi-
tion, all participants were asked to abstain from drinking or eating 
immediately before providing a sample. Whilst alpha-amylase exhib-
its a diurnal pattern, it remains relatively stable throughout the day 
following a rise in the first hours after waking.34 Participants were 
therefore instructed to provide two samples during waking hours, 
approximately 10 minutes apart to increase reliability of measure-
ment (the average coefficient of variation in alpha-amylase activity 
at baseline was 1.7% and at follow-up 1.8%).
Analysis
Data were analyzed with IBM SPSS Statistics 20.0.0. Comparisons 
were made between those who did and did not have complete base-
line and follow-up data for questionnaire items (to assess NRT 
Table 1. Baseline Characteristics
Questionnaire data Biomarker data
Available  
(N = 1047)
Lost to follow-up 
(N = 681)
Available  
(N = 258)
Lost to follow-up 
(N = 454)
Sociodemographic/health characteristics
 Mean (SD) Age 46.4 (14.0) 41.1 (13.7)*** 45.7 (13.4) 42.2 (14.6)**
 % (N) Female 55.0 (576) 53.6 (365) 51.6 (133) 48.7 (221)
 % (N) White 97.2 (1018) 94.7 (645)** 96.5 (249) 93.8 (426)
 % (N) Cohabiting 53.4 (559) 47.3 (322)* 53.9 (139) 44.9 (204)*
 % (N) Routine/manual occupation 30.9 (323) 34.5 (235) 25.2 (65) 30.6 (139)
 % (N) Degree or equivalent 10.6 (111) 10.4 (71) 10.5 (27) 9.3 (42)
 % (N) Medical condition 59.5 (622) 52.9 (360)** 57.4 (148) 58.4 (265)
Smoking characteristics
 Mean (SD) Heaviness of smoking index 3.28(1.45) 3.22 (1.46) 3.19 (1.54) 3.51 (1.41)**
 % (N) Smoking length < 10 years 10.9 (114) 17.4 (118)*** 9.3 (24) 14.3 (65)
 % (N) Quit attempt last 12 months 41.7 (434) 41.0 (275) 38.1 (98) 38.4 (172)
NHS SSS treatment characteristics
 % (N) Intervention type*
  Closed group 3.2 (34) 2.9 (20) 6.6 (17) 4.6 (21)
  Open (rolling) group 20.8 (218) 17.6 (120) 21.3 (55) 13.9 (63)
  Drop-in clinic 26.5 (277) 27.2 (185) 24.4 (63) 30.4 (138)
  One to one support 49.2 (515) 51.9 (353) 47.7 (123) 50.7 (230)
  Other 0.3 (3) 0.3 (2) 0 (0) 0.4 (2)
 % (N) Medication**
  Single NRT 17.4 (182) 17.9 (122) 17.4 (45) 15.2 (69)
  Combination NRT 12.2 (128) 15.1 (103) 16.3 (42) 27.3 (124)
  Varenicline 50.2 (526) 48.5 (330) 48.4 (125) 37.4 (170)
  Othera 19.0 (199) 17.0 (116) 16.3 (42) 19.2 (87)
  None 1.1 (12) 1.5 (10) 1.6 (4) 0.9 (4)
NRT = nicotine replacement therapy; SSS = UK Stop-Smoking Services.
aBupropion and mixed medication (mainly NRT).
*p < .05; **p < .01; ***p < .001.
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prevalence) and those who did or did not have complete baseline 
and follow-up biomarker data (to assess impact). Differences were 
assessed with chi-square tests and independent t tests for categori-
cal and continuous variables, respectively. In the prevalence analysis, 
descriptive statistics including 95% confidence intervals (95% CI) 
were calculated and, where applicable, groups compared using logis-
tic regression. To correct for nonresponse all prevalence estimates 
are weighted.25
In the biomarker analysis, due to the typically positively skewed 
distribution of cotinine and alpha-amylase values and relatively 
small sample size, geometric means and interquartile ranges were 
calculated. The nonparametric Kruskal-Wallis and Wilcoxon tests 
were used to assess between-group differences and within-group dif-
ferences (to look at change across time), respectively. In sensitivity 
analysis, findings were re-examined with generalized linear models 
for between- and within-group comparisons that used a gamma 
distribution with a log link (all zero values were replaced with 
0.001) to account for the non-normal distribution and adjusted for 
potential confounders (age, sex, ethnicity, occupation, any medical 
condition and nicotine dependence). Statistical significance was set 
at the standard level (p < .05), and the Bonferroni correction was 
applied to account for multiple comparisons and Type I error rate. 
The study received ethical approval from the South East Scotland 
Research Ethics Committee (11/AL/0256) and was carried out in 
accordance with the ethical principles on human research, as set out 
in the Declaration of Helsinki.
Results
Prevalence of Long-term NRT Use Among Current 
Smokers and Ex-smokers
Information on long-term NRT use was provided by 1047 par-
ticipants (34.4% of the total ELONS sample) who constitute the 
analytic sample for the prevalence analysis. Those who were lost 
at follow-up were younger, had smoked for a shorter period, were 
less likely to have a medical condition, to be white or cohabiting 
(Table 1). All prevalence estimates in this section are weighted.
Of clients followed-up, 61.5% (95% CI 58.4%–64.6%, N = 583) 
reported using NRT during their initial quit attempt. This figure 
was somewhat higher than the recorded NRT use in SSS (around 
N = 500 when including the “Other” category in Table 1), suggesting 
that some participants had obtained additional NRT over the coun-
ter. Figure 1A provides a breakdown of clients in terms of the length 
of use of NRT and as a function of smoking status at follow-up. As 
can be seen, most clients who started on NRT used it for at least 8 
weeks and more than one in five (21.5%, 95% CI 18.3%–25.0%, 
N = 137) for longer than the standard 12 weeks. However, long-term 
use was relatively rare with less than 1 in 10 participants still using 
noncombustible nicotine delivery devices at 12-month follow-up 
Figure 1. (A) Nicotine replacement therapy (NRT) use across follow-up period among those who had used NRT during initial quit attempt (N = 583)*; (B) Product 
type used among those with long-term NRT use at follow-up (N = 50). *Includes e-cigarettes (users of products at 12-month provide denominator for Figure 1B); 
†No use of nicotine nasal spray reported at 12-month follow-up; users could indicate multiple products; Error bars are 95% confidence intervals.
Nicotine & Tobacco Research, 2016, Vol. 00, No. 00 5
(8.4%, 95% CI 6.4%–11.0%, N  =  50), including both NRT and 
e-cigarettes. In this sample, NRT use was twice as prevalent (6.0%, 
95% CI 4.3%–8.3%, N = 35) as use of e-cigarettes at 12 months 
(2.9%, 95% CI 1.8%–4.7%, N = 18; some participants were dual 
product users).
Generally, the pattern of NRT use across the study period was rela-
tively similar for those who had remained abstinent and those who had 
relapsed by 12-month follow-up (Figure 1A). However, ex-smokers had 
higher rates of NRT use compared with relapsers at all time-points. At 
12-month follow-up, long-term ex-smokers were over four-times more 
likely than relapsers to be still using noncombustible nicotine deliv-
ery devices (OR 4.25, 95% CI 2.15–8.40, p < .001): 14.0% (95% CI 
10.3%–18.7%, N = 38) of ex-smokers were still using these compared 
with 3.7% (95% CI 2.0%–6.5%, N = 12) of relapsers. This difference, 
while being attenuated, remained significant when excluding those 
who used e-cigarettes only (OR 2.91, 95% CI 1.38–6.11, p =  .005) 
with 9.5% (95% CI 6.4%–13.8%, N = 25) of ex-smokers and 3.5% 
(95% CI 1.9%–6.3%, N = 10) of relapsers still using NRT, respectively. 
Comparing the quitters and relapsers who were or were not using NRT 
at follow-up in terms of the characteristics presented in Table 1 showed 
that dependence was the only variable (other than medication use, as 
would be expected) that differed between groups (F(3, 1037) = 5.52, p 
< .001). Relapsers without NRT use had significantly higher depend-
ence scores than quitters, irrespective of their NRT use.
When looking at individual nicotine-delivery devices still used at 
12-month follow-up, e-cigarettes were the most popular, followed 
by the nicotine lozenge, patch, and gum (Figure 1B). No one used 
the nasal spray, possibly due to the higher cost of the nasal spray 
compared with other NRT products, and 16.8% were using multi-
ple products. Due to the small numbers involved, there was insuffi-
cient power to detect meaningful differences between those who had 
remained abstinent and those who had relapsed.
Impact of Long-term NRT Use on Biomarkers of 
Nicotine Exposure and Stress Among Current 
Smokers and Ex-smokers
Baseline and follow-up saliva samples were provided by 258 partici-
pants (8.5% of the total sample) who constitute the analytic sample 
for the biomarker analysis. Those lost to follow-up were younger, 
less likely to be cohabiting and there were some differences in the 
treatments used; they were also more dependent (Table 1).
There were no differences in baseline cotinine levels between 
any of the groups (Table 2). This was confirmed in adjusted analy-
sis controlling for potential confounders which showed that older 
age (Wald χ2 (1) = 6.6, p = .011) and greater dependence (Wald χ2 
(1) = 26.7, p < .001) were the only significant predictors of baseline 
cotinine levels. Similarly, there were no group differences in baseline 
alpha-amylase levels, again confirmed in adjusted analysis (Table 2). 
This showed that older age (Wald χ2 (1)  = 10.6, p  =  .001), being 
non-white (Wald χ2 (1)  =  5.3, p  =  .022) and having any medical 
condition (Wald χ2 (1) = 9.8, p = .002) were associated with higher 
alpha-amylase activity at baseline.
At follow-up, there was a clear difference between groups in coti-
nine levels (Kruskal Wallis H (3)  =  130.2, p < .001). Ex-smokers 
using no NRT had significantly lower cotinine values at follow-up 
than all other groups (Table 2). Adjusted analysis confirmed these 
group differences (Wald χ2 (3) = 78.9, p < .001) and showed base-
line nicotine dependence as the only additional significant predictor 
of follow-up cotinine levels (Wald χ2 (1) = 15.4, p < .001). There 
were no group differences in follow-up alpha-amylase levels which 
was confirmed in adjusted analysis (Table 2); only greater nicotine 
dependence at baseline was positively associated with follow-up 
alpha-amylase activity (Wald χ2 (1) = 8.1, p = .004).
In addition to the cross-sectional analyses for baseline and 
follow-up data reported above, we also examined within-person 
changes from baseline to follow-up in longitudinal analysis (please 
note that this group is slightly smaller as not all participants who 
provided both baseline and follow-up saliva samples had provided 
either two samples at each time point or samples that were viable). 
As shown in Figure  2A, cotinine levels significantly reduced from 
baseline to follow-up only in ex-smokers not using NRT at follow-
up (Standardized Z  =  −9.9, p < .001) and not in other groups. 
Adjusted analysis confirmed the significant NRT use by smoking 
status interaction for changes in cotinine levels (Wald χ2 (1) = 13.0, 
p < .001) and also showed that greater baseline age (Wald χ2 
(1) = 4.3, p = .037) and dependence (Wald χ2 (1) = 44.8, p < .001) 
were associated with an increase in cotinine levels.
While unadjusted analysis indicated that there was an increase in 
alpha-amylase activity from baseline to follow-up in ex-smokers not 
using NRT at follow-up (Standardized Z = 3.0, p = .003) and not in 
other groups (Figure 2B), this was not confirmed in adjusted analy-
sis. Neither the NRT use by smoking status interaction for changes 
in alpha-amylase levels (Wald χ2 (1) = 2.1, p = .147) nor main effects 
for NRT use (Wald χ2 (1) = 0.9, p = .352) or smoking status (Wald 
χ2 (1) = 0.8, p =  .373) were significant. However, greater baseline 
age (Wald χ2 (1) = 4.4, p < .036), dependence (Wald χ2 (1) = 6.0, 
p = .014) and reporting any medical condition at baseline (Wald χ2 
(1) = 5.8, p = .016) were independently associated with an increase 
in alpha-amylase activity.
Table 2. Biomarker Results by Follow-up NRT Use and Follow-up Smoking Status
Smokers (relapsers) Ex-smokers (quitters)
NRT use (N = 18) No NRT use (N = 73) NRT use (N = 14) No NRT use (N = 153)
Baseline assessment
 Geometric mean (IQR/n) cotinine in ng/mL 193.7 (323.1/17) 241.1 (238.8/68) 340.1 (163.9/13) 197.6 (174.6/146)
 Geometric mean (IQR/n) alpha-amylase in U/mL 20.1 (59.1/12) 21.8 (27.2/45) 29.1 (14.2/11) 23.6 (30.5/109)
Follow-up assessment
 Geometric mean (IQR/n) cotinine in ng/ml 210.8 (240.0/16)a 244.7 (198.7/69)a 169.9 (449.6/10)a 1.2 (21.6/149)b
 Geometric mean (IQR/n) alpha-amylase in U/mL 25.8 (69.6/13) 26.7 (32.2/43) 22.4 (49.7/10) 27.6 (37.7/111)
IQR = interquartile range; NRT = nicotine replacement therapy.
a,bDifferent letters indicate significant differences between groups(p < .05).
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Discussion
Extended use of NRT among SSS clients was relatively prevalent, 
with over one in five who achieve short-term abstinence continuing 
to use it beyond the standard treatment length of 3 months, but con-
tinued long-term use of NRT by those who achieve long-term absti-
nence at one year is less common at just below 10%. Nonetheless, 
given that 1-year usage rates were estimated at around 5% among 
ex-smokers who attend SSS in 2002,35 this suggests that recent policy 
and licensing changes in favor of harm reduction9,10,12 may have had 
some impact on long-term NRT use among services users. This con-
trasts with a lack of change in NRT usage pattern observed in the 
general population following an earlier relaxation of NRT licensing 
in 2005.36 However, the low 4% prevalence of concurrent long-term 
use of NRT among SSS clients who had relapsed is similar to figures 
from the general population suggesting that longer-term NRT use 
among smokers is rare.37 Indeed, concurrent NRT use among smok-
ers, either for temporary abstinence or cutting down, has remained 
relatively stable since 2002,38 with most smokers using NRT for less 
than 3 months.37
Interestingly, despite a steady increase in the prevalence of e-cig-
arette use among smokers and ex-smokers in the United Kingdom,39 
the long-term use of e-cigarettes among past SSS clients in this study 
was surprisingly low at less than 3% compared with estimates of 
one in five smokers or recent ex-smokers using e-cigarettes in the 
general population.40 However, this may be due to the specificity of 
the sample selection and the timing of the study, being conducted 
around the time of increasing awareness of e-cigarettes in the United 
Kingdom but before use became widespread amongst smokers and 
recent quitters.41
This study provides some rare insights in the exposure to nicotine 
associated with long-term dual or single use of NRT, as well as its 
impact on a biological index of stress, alpha-amylase. Clinical trials 
suggest that permanent replacement of cigarettes with NRT among 
ex-smokers can result in 40% of baseline levels of nicotine being 
substituted by nicotine replacement products long-term.42,43 Our 
findings not only confirm substantial substitution of nicotine from 
cigarettes with nicotine from NRT but, given the lack of changes 
in ex-smokers using NRT from baseline to follow-up, suggest that 
virtually all baseline nicotine may be replaced by NRT among long-
term ex-smokers. This increase in substitution levels compared with 
previous work may reflect differences in our sample or changes in 
the NRT products available. It is unlikely to be the result of other 
product use as all ex-smokers were carbon monoxide-verified and 
participants with concurrent use of other nicotine delivery devices, 
that is, e-cigarettes, were excluded.
Confirming previous research,5,44 the concurrent use of NRT 
among smokers did not appear to increase their nicotine intake. 
These findings are in agreement with the hypothesis that smokers are 
very adept at titrating nicotine levels, with some nicotine otherwise 
obtained from cigarettes being replaced by nicotine from NRT.45 
However, our results indicate this also applies to ex-smokers, which 
is consistent with a strong genetic component in nicotine intake46 
but at odds with clinical42 and general population studies6 showing 
that nicotine substitution from NRT tapers off over time. Behavioral 
support in SSS includes detailed instructions on the correct use of 
NRT47 which is not available in other settings and may explain the 
differential in both NRT effectiveness and associated nicotine intake 
when used with and without behavioral support.
Although it is unlikely that a substantially increased nicotine 
intake from NRT would be harmful,48,49 it clearly is a concern for 
some people and a potential barrier to effective use of nicotine prod-
ucts.16 Our results not only suggest that dual use with NRT does not 
increased nicotine intake compared with continued smoking, they 
also indicate that use of NRT (either with or without concurrent 
smoking) is not associated with an increase in a biomarker of stress 
response, alpha-amylase, used as a proxy here to signal potential 
harm. Given observed reductions in stress levels in smokers fol-
lowing cessation,50 it was surprising not to see any reductions of 
alpha-amylase levels in quitters. However, it should be noted that 
tobacco smoke has been shown to acutely inhibit alpha amylase 
activity,33 which means that the benefit of smoking cessation may 
have been masked by the impact of baseline smoking. Moreover, 
spot sampling may not be reliable enough to pick up true long-term 
changes. While there was an expected association of increased bio-
logical stress with older age and having a medical condition, the 
association of increased alpha-amylase activity with greater baseline 
nicotine dependence was not predicted and deserves further investi-
gation as it suggests that the stress response is dependence-mediated 
(rather than nicotine-mediated). Altogether, these findings are con-
sistent with the view that long-term NRT use is safe and not associ-
ated with increased health risks, certainly compared with continued 
smoking.21
This study has a number of limitations. Despite an initial large 
sample size, drop out across the study was inevitably substantial, 
resulting in relatively few clients with complete baseline and follow-up 
Figure 2. Change in (A) cotinine levels (N = 232) and (B) alpha-amylase activity 
(N = 166) from baseline to follow-up as a function of nicotine replacement 
therapy (NRT) use and smoking status at follow-up. Data not available from 
N participants due to insufficient samples or contamination: *26 cases; †92 
cases; Error bars are interquartile range.
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data on biomarkers. In addition, the baseline sample differed from the 
sample followed up. However, differences were relatively modest, and 
prevalence data were weighted to account for differential drop out. 
As clients self-selected into groups rather than being experimentally 
assigned, we cannot exclude potential reverse causation, for example, 
particular individuals who happen to have a high sensitivity to nico-
tine intake may use NRT for longer. Moreover, we were only able to 
assess current NRT use but not frequency of NRT use at follow-up 
which means that it is difficult to ascertain how comparable NRT use 
was across relapsers and quitters. However, this study reflects real-
world use of NRT and the longitudinal within-group design reduced 
confounding by allowing participants to be their own control. Lastly, 
different methodologies were used to collect follow-up saliva samples 
which may have impacted results. However, the same clear instruc-
tions were provided to participants and researchers for postal and 
face-to-face collection, respectively. All assessments were carried out 
with established, ecologically valid measures and smoking status veri-
fied, but further research would benefit from measuring a wider array 
of biomarkers of smoking-related harm, including different biomark-
ers of chronic stress such as cortisol.
In conclusion, among former SSS clients long-term NRT use by 
ex-smokers is relatively rare but more common than use by smokers. 
Furthermore, long-term use seems to have increased since the introduc-
tion of harm reduction guidance in the United Kingdom. Long-term 
use of NRT does not appear to have a detrimental effect on chronic 
stress response among smokers or ex-smokers and does not increase 
overall nicotine intake in smokers but is associated with continued 
nicotine intake in ex-smokers, comparable to when they were smoking.
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